用于治疗自身免疫性和炎性疾病的酪氨酸激酶2（TYK2）抑制剂
TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Feb 6;15(3):320-321. doi: 10.1021/acsmedchemlett.4c00024. eCollection 2024 Mar 14.
Abstract
Provided herein are novel TYK2 inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, and processes for preparing such compounds.
摘要
本文提供了新型酪氨酸激酶2（TYK2）抑制剂、药物组合物、此类化合物在治疗自身免疫性疾病和炎性疾病中的用途，以及制备此类化合物的方法。
相似文献
1
TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Feb 6;15(3):320-321. doi: 10.1021/acsmedchemlett.4c00024. eCollection 2024 Mar 14.
2
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Dec 9;16(1):8-9. doi: 10.1021/acsmedchemlett.4c00566. eCollection 2025 Jan 9.
3
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Jan 26;15(2):177-178. doi: 10.1021/acsmedchemlett.4c00011. eCollection 2024 Feb 8.
4
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 May 16;15(6):769-770. doi: 10.1021/acsmedchemlett.4c00196. eCollection 2024 Jun 13.
5
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Apr 23;15(5):581-582. doi: 10.1021/acsmedchemlett.4c00169. eCollection 2024 May 9.
6
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2024 Feb 14;15(3):322-323. doi: 10.1021/acsmedchemlett.4c00044. eCollection 2024 Mar 14.
7
Novel Tetrahydropyrido[3,4-]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases.
ACS Med Chem Lett. 2024 Jan 31;15(3):318-319. doi: 10.1021/acsmedchemlett.4c00023. eCollection 2024 Mar 14.
8
Novel Pyrido[3,2-]pyrimidines as HPK1 Inhibitors for Treating Cancer and Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2023 Nov 27;14(12):1627-1628. doi: 10.1021/acsmedchemlett.3c00506. eCollection 2023 Dec 14.
9
Tyrosine kinase 2 inhibitors in autoimmune diseases.
Autoimmun Rev. 2024 Nov;23(11):103649. doi: 10.1016/j.autrev.2024.103649. Epub 2024 Sep 29.
10
Novel Thienopyrrole Compounds for Treating Autoimmune Diseases and Inflammatory Conditions.
ACS Med Chem Lett. 2023 Apr 20;14(5):549-550. doi: 10.1021/acsmedchemlett.3c00131. eCollection 2023 May 11.
引用本文的文献
1
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 May 16;15(6):769-770. doi: 10.1021/acsmedchemlett.4c00196. eCollection 2024 Jun 13.
本文引用的文献
1
Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease.
Int Immunopharmacol. 2024 Jan 5;126:111238. doi: 10.1016/j.intimp.2023.111238. Epub 2023 Nov 20.
2
Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Biomed Pharmacother. 2023 Nov;167:115611. doi: 10.1016/j.biopha.2023.115611. Epub 2023 Sep 29.
3
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets.
MedComm (2020). 2023 Sep 11;4(5):e349. doi: 10.1002/mco2.349. eCollection 2023 Oct.
4
Ubiquitination network in the type I IFN-induced antiviral signaling pathway.
Eur J Immunol. 2023 Sep;53(9):e2350384. doi: 10.1002/eji.202350384. Epub 2023 May 28.
5
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Pharmacol Res. 2023 Mar;189:106642. doi: 10.1016/j.phrs.2022.106642. Epub 2023 Feb 6.
Zotero 插件